Advertisement
Logo
Search for

Volume 149, Issue 2, Pages 316-321.e1 (1 February 2010)


View previous. 23 of 33 View next.

Subretinal Hemorrhages Associated with Age-Related Macular Degeneration in Patients Receiving Anticoagulation or Antiplatelet Therapy

Claudia Kuhli-HattenbachaCorresponding Author Informationemail address, Ina Barbara Fischera, Rainer Schalnusa, Lars-Olof Hattenbachab

Accepted 28 August 2009. published online 24 November 2009.

Purpose

To evaluate the incidence of and risk factors for subretinal hemorrhages in age-related macular degeneration (AMD) patients on anticoagulation or antiplatelet therapy.

Design

Retrospective, observational case series.

Methods

We retrospectively reviewed the medical and photographic records of 71 consecutive patients who sought treatment at our institution with acute subretinal hemorrhages complicating age-related macular degeneration. The size of the subretinal hemorrhage was measured in standardized Macular Photocoagulation Study disc areas. Data on the use of medications and medical indications for anticoagulation and antiplatelet therapy were obtained.

Results

Overall, patients receiving antithrombotic therapy had a significantly larger subretinal hemorrhage size (mean, 9.71 disc areas) than patients not receiving anticoagulant or antiplatelet therapy (mean, 2.99 disc areas). Subgroup analysis revealed that both antiplatelet (P < .0001) and anticoagulant therapy (P = .003) were associated with a significantly larger bleeding size. Moreover, subgroup analysis among patients with arterial hypertension revealed that individuals receiving antithrombotic therapy had a statistically significantly larger hemorrhage size than hypertensive patients who did not receive anticoagulants or antiplatelet agents (P < .0001).

Conclusions

Our results indicate that anticoagulants and antiplatelet agents are strongly associated with the development of large subretinal hemorrhages in AMD patients. Moreover, arterial hypertension is a strong risk factor for large subretinal hemorrhages in AMD patients receiving anticoagulants or antiplatelet agents. Physicians should be aware of an increased risk of extensive subretinal hemorrhage in AMD patients when deciding on the initiation and duration of anticoagulant and antiplatelet therapy.

a Klinik für Augenheilkunde, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany

b Augenklinik des Klinikums Ludwigshafen, Ludwigshafen am Rhein, Germany

Corresponding Author InformationInquiries to Claudia Kuhli-Hattenbach, Department of Ophthalmology, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany

PII: S0002-9394(09)00659-X

doi:10.1016/j.ajo.2009.08.033


View previous. 23 of 33 View next.

Advertisement